Alterity Therapeutics CEO to Present at Canaccord Genuity Conference…

Event summary

Alterity Therapeutics CEO David Stamler to present at Canaccord Genuity Drug and Device Conference on October 12, 2026.
Presentation includes corporate update and investor roundtable discussions.
Alterity is preparing to initiate a Phase 3 pivotal trial for its lead asset ATH434 in Multiple System Atrophy (MSA).
Company has reported positive data from Phase 2 clinical trials in MSA.

The big picture

Alterity Therapeutics' upcoming presentation at the Canaccord Genuity conference comes as the company prepares to initiate a pivotal Phase 3 trial for its lead asset ATH434. The focus on neurodegenerative diseases, particularly MSA, positions Alterity in a niche but high-need market. The company's progress in clinical trials will be closely watched by investors and industry observers, as successful outcomes could significantly enhance its valuation and strategic partnerships.

What we're watching

Clinical Progress: The pace at which Alterity advances its Phase 3 trial for ATH434 will determine its path to regulatory approval.
Investor Sentiment: How investor discussions at the conference impact market perception of Alterity's pipeline and financial prospects.
Competitive Positioning: Whether Alterity can maintain its lead in developing disease-modifying therapies for MSA amid potential competitors.